Targeting Peritoneal Metastases from Two Directions: The Promise of NIPS
Normothermic Intraperitoneal and Systemic Treatment (NIPS) Using Paclitaxel for Peritoneal Metastases from Gastrointestinal CancerJournal: Cancers, 2026; 18(13):2166DOI: 10.3390/cancers18132166
When gastrointestinal cancers spread to the lining of the abdomen, known as the peritoneum, treatment can be especially challenging. A new review published in Cancers examines an approach called normothermic intraperitoneal and systemic treatment (NIPS), which combines chemotherapy delivered directly into the abdominal cavity with chemotherapy that circulates throughout the body. The review focuses particularly on the use of the chemotherapy drug paclitaxel for peritoneal metastases from gastrointestinal cancers.
Why can peritoneal metastases be difficult to treat?
Systemic chemotherapy travels through the bloodstream, but peritoneal tumors often have relatively poor blood flow. In addition, a structure known as the peritoneal–plasma barrier can limit how much systemically administered chemotherapy reaches tumors on the peritoneal surface. This may help explain why peritoneal metastases can be more difficult to treat than cancer that has spread to some other organs.
Delivering chemotherapy directly into the abdominal cavity is one way researchers have tried to overcome this problem. Treatments such as HIPEC and PIPAC also use intraperitoneal chemotherapy, but they require surgical or laparoscopic procedures. NIPS takes a different approach.
What is NIPS?
With NIPS, a small access port and catheter are implanted into the abdomen. Chemotherapy can then be given directly into the peritoneal cavity repeatedly—often alongside intravenous or oral chemotherapy.
Unlike HIPEC, which is typically delivered during cytoreductive surgery, NIPS can be administered repeatedly over time without requiring an operation or general anesthesia for each treatment. The implanted port can also allow doctors to collect peritoneal fluid to monitor the disease.

Paclitaxel may be particularly useful for this approach because it remains in the abdominal cavity for a relatively long period after being administered intraperitoneally. This allows the peritoneal surfaces to be exposed to high concentrations of the drug while limiting the amount that reaches the rest of the body. Studies cited in the review found that paclitaxel can remain at potentially therapeutic concentrations in the peritoneal cavity for several days.
Why combine intraperitoneal and systemic chemotherapy?
Intraperitoneal chemotherapy has an important limitation: the drug generally penetrates only a relatively short distance into tumor nodules. That means it may be most effective against small or superficial deposits rather than large or deeply invasive tumors.
Combining intraperitoneal treatment with systemic chemotherapy may help address the cancer from two directions. Chemotherapy placed in the abdomen targets the surface of peritoneal tumors, while systemic treatment can reach cancer cells through the bloodstream and address disease elsewhere in the body. This complementary approach is the central idea behind NIPS.
What has research shown so far?
The strongest evidence described in the review comes from gastric cancer with peritoneal metastases. Several studies have reported encouraging survival and disease-control results with paclitaxel-based NIPS. In the recent randomized phase III DRAGON-01 trial, patients receiving intraperitoneal paclitaxel together with systemic treatment had a median overall survival of 19.4 months compared with 13.9 months for patients receiving systemic chemotherapy alone.
Another potentially important finding is that some patients experienced enough improvement in their peritoneal disease to become candidates for surgery. Across gastric cancer studies reviewed in the article, conversion from positive to negative peritoneal cytology occurred frequently, and approximately 26% to 63% of patients in individual studies were ultimately able to undergo conversion gastrectomy. These results raise the possibility that regional treatment could help some carefully selected patients move from initially unresectable disease toward surgery.
Studies in pancreatic and colorectal cancers have also produced encouraging early results, but the evidence is considerably less mature. For colorectal cancer in particular, the authors describe NIPS as an experimental approach, while treatments such as cytoreductive surgery with HIPEC and PIPAC currently have a more established role in appropriately selected patients.
What should patients know?
This review does not show that NIPS should replace established treatments such as systemic chemotherapy, CRS/HIPEC, or other approaches. It is also important to recognize that this publication is a narrative review of existing research rather than a new clinical trial.
The strength of the evidence differs significantly by cancer type. Gastric cancer currently has the strongest evidence, including randomized studies. Evidence for pancreatic and colorectal cancers remains earlier-stage, and additional prospective and randomized trials are needed before NIPS can be considered a routine treatment option across gastrointestinal cancers.
The Takeaway
Paclitaxel-based NIPS represents a promising strategy for addressing one of the central challenges of peritoneal metastases: getting enough chemotherapy directly to cancer growing within the abdominal cavity.
By combining repeated intraperitoneal chemotherapy with systemic treatment, researchers hope to improve control of peritoneal disease while maintaining treatment throughout the rest of the body. Early results—particularly in gastric cancer—are encouraging, and some patients have responded well enough to later become candidates for surgery.
For patients facing peritoneal metastases, the research also reinforces the importance of evaluation by a multidisciplinary team experienced in peritoneal surface malignancies, where treatments such as systemic therapy, CRS/HIPEC, PIPAC, clinical trials, and emerging approaches like NIPS can be considered based on the individual patient's cancer, disease burden, and overall health.



